Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Three-Compartment Open Model01:06

Three-Compartment Open Model

The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards quantitative intensity analysis of conventional T1-weighted images in multiple sclerosis.

NeuroImage·2025
Same author

Improving risk assessment of local failure in brain metastases patients using vision transformers - A multicentric development and validation study.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Corrigendum to "Outcome and risk of hemorrhage in patients with tandem lesions after endovascular treatment: A propensity score-matched case-control study" [Heliyon Volume 9, Issue 3, March 2023, Article e14508].

Heliyon·2025
Same author

Data extraction from free-text stroke CT reports using GPT-4o and Llama-3.3-70B: the impact of annotation guidelines.

European radiology experimental·2025
Same author

Boosting LLM-assisted diagnosis: 10-minute LLM tutorial elevates radiology residents' performance in brain MRI interpretation.

Neuroradiology·2025
Same author

Investigating the effects of brain stimulation on the neural substrates of inhibition in patients with OCD: A simultaneous tDCS - fMRI study.

Translational psychiatry·2025

Related Experiment Video

Updated: Jul 13, 2026

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

Pharmacokinetic modeling of Gd-DTPA extravasation in brain tumors.

Lutz Ludemann1, Reinhard Wurm, Claus Zimmer

  • 1Department of Radiology and Neuroradiology, CCM Universitätsklinikum Charité, Berlin, Germany. lutz.luedemann@charite.de

Investigative Radiology
|September 28, 2002
PubMed
Summary

Dynamic contrast enhanced MRI quantifies brain tumor blood-brain barrier permeability. Two distinct transport processes were identified, differentiating tumor types like gliomas and meningiomas based on contrast medium exchange rates.

More Related Videos

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

Related Experiment Videos

Last Updated: Jul 13, 2026

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

Area of Science:

  • Neuroimaging
  • Oncology
  • Radiology

Background:

  • The blood-brain barrier (BBB) is crucial for brain function, but its integrity is compromised in brain tumors.
  • Assessing endothelial permeability of brain tumors is vital for diagnosis and treatment planning.

Purpose of the Study:

  • To quantify endothelial permeability in brain tumors using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).
  • To investigate the dynamics of contrast medium (CM) exchange in intra-axial and extra-axial brain tumors.
  • To determine exchange rates and saturation concentrations for characterizing tumor microvasculature.

Main Methods:

  • Utilized fast repeated T1-weighted imaging in 31 brain tumors (intra- and extra-axial).
  • Analyzed contrast medium (CM) exchange dynamics to derive transfer constants and saturation concentrations.
  • Compared CM exchange parameters between different tumor types, including gliomas and meningiomas.

Main Results:

  • Identified two distinct CM transport processes into interstitial subcompartments for intra- and extra-axial tumors.
  • Characterized a rapid transport process (1/k = 7.0 seconds) and a slow process (1/k = 133.7 seconds).
  • Demonstrated highly significant differences in saturation concentrations between gliomas and meningiomas for both fast and slow compartments.

Conclusions:

  • The rapid CM transport component likely represents extravasation into viable tumor tissue, prominent in meningiomas.
  • The slow component is attributed to increased diffusion distances in poorly perfused or necrotic tumor areas, such as in glioblastomas.
  • DCE-MRI provides valuable insights into tumor pathophysiology by differentiating transport mechanisms and characterizing tissue perfusion.